Search Results

There are 123400 results for: content related to: How cutaneous eruptions help to understand the mode of action of kinase inhibitors

  1. You have free access to this content
    BRAF, a target in melanoma

    Cancer

    Volume 116, Issue 21, 1 November 2010, Pages: 4902–4913, Keith T. Flaherty and Grant McArthur

    Version of Record online : 13 JUL 2010, DOI: 10.1002/cncr.25261

  2. You have free access to this content
    Targeting RAS/RAF/MEK/ERK signaling in metastatic melanoma

    IUBMB Life

    Volume 65, Issue 9, September 2013, Pages: 748–758, Ao-Xue Wang and Xiao-Yi Qi

    Version of Record online : 29 JUL 2013, DOI: 10.1002/iub.1193

  3. You have free access to this content
    Society for Melanoma Research 2015 Congress

    Pigment Cell & Melanoma Research

    Volume 28, Issue 6, November 2015, Pages: 753–826,

    Version of Record online : 17 OCT 2015, DOI: 10.1111/pcmr.12419

  4. Treatment of BRAF-Mutant Melanoma: The Role of Vemurafenib and Other Therapies

    Clinical Pharmacology & Therapeutics

    Volume 95, Issue 1, January 2014, Pages: 24–31, S Jang and MB Atkins

    Version of Record online : 19 DEC 2013, DOI: 10.1038/clpt.2013.197

  5. You have free access to this content
    Time to re-consider the meaning of BRAF V600E mutation in papillary thyroid carcinoma

    International Journal of Cancer

    Volume 137, Issue 5, 1 September 2015, Pages: 1001–1011, Greta Gandolfi, Valentina Sancisi, Simonetta Piana and Alessia Ciarrocchi

    Version of Record online : 27 MAY 2014, DOI: 10.1002/ijc.28976

  6. The broad-spectrum receptor tyrosine kinase inhibitor dovitinib suppresses growth of BRAF-mutant melanoma cells in combination with other signaling pathway inhibitors

    Pigment Cell & Melanoma Research

    Volume 28, Issue 4, July 2015, Pages: 417–430, Casey G. Langdon, Matthew A. Held, James T. Platt, Katrina Meeth, Pinar Iyidogan, Ramanaiah Mamillapalli, Andrew B. Koo, Michael Klein, Zongzhi Liu, Marcus W. Bosenberg and David F. Stern

    Version of Record online : 6 MAY 2015, DOI: 10.1111/pcmr.12376

  7. You have free access to this content
    New drug targets in metastatic melanoma

    The Journal of Pathology

    Volume 232, Issue 2, January 2014, Pages: 134–141, Blanca Homet and Antoni Ribas

    Version of Record online : 10 DEC 2013, DOI: 10.1002/path.4259

  8. Phosphoproteomic analysis of basal and therapy-induced adaptive signaling networks in BRAF and NRAS mutant melanoma

    PROTEOMICS

    Volume 15, Issue 2-3, January 2015, Pages: 327–339, Inna V. Fedorenko, Bin Fang, Ana Cecelia Munko, Geoffrey T. Gibney, John M. Koomen and Keiran S. M. Smalley

    Version of Record online : 17 DEC 2014, DOI: 10.1002/pmic.201400200

  9. You have free access to this content
    That which does not kill me makes me stronger; combining ERK1/2 pathway inhibitors and BH3 mimetics to kill tumour cells and prevent acquired resistance

    British Journal of Pharmacology

    Volume 169, Issue 8, August 2013, Pages: 1708–1722, Matthew J Sale and Simon J Cook

    Version of Record online : 26 JUL 2013, DOI: 10.1111/bph.12220

  10. You have free access to this content
    Clinicopathologic features associated with efficacy and long-term survival in metastatic melanoma patients treated with BRAF or combined BRAF and MEK inhibitors

    Cancer

    Volume 121, Issue 21, November 1, 2015, Pages: 3826–3835, Alexander M. Menzies, James S. Wilmott, Martin Drummond, Serigne Lo, Megan Lyle, Matthew M. K. Chan, John F. Thompson, Alex Guminski, Matteo S. Carlino, Richard A. Scolyer, Richard F. Kefford and Georgina V. Long

    Version of Record online : 28 JUL 2015, DOI: 10.1002/cncr.29586

  11. Cutaneous adverse events in patients treated with BRAF inhibitor-based therapies for metastatic melanoma for longer than 52 weeks

    British Journal of Dermatology

    Volume 172, Issue 1, January 2015, Pages: 239–243, R. Anforth, G. Carlos, A. Clements, R. Kefford and P. Fernandez-Peñas

    Version of Record online : 21 NOV 2014, DOI: 10.1111/bjd.13200

  12. You have free access to this content
    A new era: melanoma genetics and therapeutics

    The Journal of Pathology

    Volume 223, Issue 2, January 2011, Pages: 242–251, Justin M Ko and David E Fisher

    Version of Record online : 28 OCT 2010, DOI: 10.1002/path.2804

  13. You have free access to this content
    NRAS mutation status is an independent prognostic factor in metastatic melanoma

    Cancer

    Volume 118, Issue 16, 15 August 2012, Pages: 4014–4023, John A. Jakob, Roland L. Bassett Jr., Chaan S. Ng, Jonathan L. Curry, Richard W. Joseph, Gladys C. Alvarado, Michelle L. Rohlfs, Jessie Richard, Jeffrey E. Gershenwald, Kevin B. Kim, Alexander J. Lazar, Patrick Hwu and Michael A. Davies

    Version of Record online : 16 DEC 2011, DOI: 10.1002/cncr.26724

  14. Prognostic and predictive values of oncogenic BRAF, NRAS, c-KIT and MITF in cutaneous and mucous melanoma

    Journal of the European Academy of Dermatology and Venereology

    Volume 29, Issue 8, August 2015, Pages: 1530–1538, M. Pracht, A. Mogha, A. Lespagnol, A. Fautrel, N. Mouchet, F. Le Gall, V. Paumier, C. Lefeuvre-Plesse, N. Rioux-Leclerc, J. Mosser, E. Oger, H. Adamski, M.-D. Galibert and T. Lesimple

    Version of Record online : 26 JAN 2015, DOI: 10.1111/jdv.12910

  15. You have free access to this content
    KRAS and BRAF: drug targets and predictive biomarkers

    The Journal of Pathology

    Volume 223, Issue 2, January 2011, Pages: 220–230, Efsevia Vakiani and David B Solit

    Version of Record online : 28 OCT 2010, DOI: 10.1002/path.2796

  16. You have free access to this content
    Role and therapeutic potential of PI3K-mTOR signaling in de novo resistance to BRAF inhibition

    Pigment Cell & Melanoma Research

    Volume 25, Issue 2, March 2012, Pages: 248–258, W. Deng, Y. N. Vashisht Gopal, A. Scott, G. Chen, S. E. Woodman and M. A. Davies

    Version of Record online : 12 JAN 2012, DOI: 10.1111/j.1755-148X.2011.00950.x

  17. BRAF mutation status in primary and metastatic melanomas in two regions with differing potential ultraviolet radiation exposure

    Clinical and Experimental Dermatology

    Volume 39, Issue 8, December 2014, Pages: 932–943, C. Massad, A. Loya, S. Taraif, M. Saroufim, A. G. Kibbi, R. Habib, M. Novy, B. Rauscher, C. Oberkanins and I. Khalifeh

    Version of Record online : 29 SEP 2014, DOI: 10.1111/ced.12430

  18. Validation of the VE1 immunostain for the BRAFV600E mutation in melanoma

    Journal of Cutaneous Pathology

    Volume 41, Issue 9, September 2014, Pages: 724–732, Michelle V. Pearlstein, Daniel C. Zedek, David W. Ollila, Amanda Treece, Margaret L. Gulley, Pamela A. Groben and Nancy E. Thomas

    Version of Record online : 4 JUL 2014, DOI: 10.1111/cup.12364

  19. You have free access to this content
    Society for Melanoma Research 2012 Congress

    Pigment Cell & Melanoma Research

    Volume 25, Issue 6, November 2012, Pages: 836–903,

    Version of Record online : 19 OCT 2012, DOI: 10.1111/pcmr.12023

  20. You have free access to this content
    The role of BRAF mutations in primary melanoma growth rate and survival

    British Journal of Dermatology

    Volume 173, Issue 1, July 2015, Pages: 76–82, V.J. Mar, W. Liu, B. Devitt, S.Q. Wong, A. Dobrovic, G.A. McArthur, R. Wolfe and J.W. Kelly

    Version of Record online : 13 JUN 2015, DOI: 10.1111/bjd.13756